Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Somatostatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 535,602Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AtomVie Delivers First 225Ac-SSO110 Dose for Ariceum Ph1/2 Trial
    AtomVie Delivers First 225Ac-SSO110 Dose for Ariceum Ph1/2 Trial

    12 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atomvie-global-radiopharma-supplies-the-first-patient-dose-of-225ac-sso110-for-ariceum-therapeutics-phase-12-santana-225-clinical-trial-in-extensive-stage-small-cell-lung-cancer-and-merkel-cell-carcinoma-302612102.html

    PR NEWSWIRE
    12 Nov 2025
    Share Share
    ITM Reveals Higher Response Rates Of (ITM-11) Vs. Everolimus
    ITM Reveals Higher Response Rates Of (ITM-11) Vs. Everolimus

    25 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/25/3174139/0/en/ITM-Announces-Analyses-from-Phase-3-COMPETE-Data-Showing-Higher-Objective-Response-Rates-with-n-c-a-177Lu-edotreotide-ITM-11-vs-Everolimus-Across-Subgroups-of-Patients-with-GEP-NET.html

    GLOBENEWSWIRE
    25 Oct 2025
    Share Share
    Results from Amyrt’s Phase 3 Trial of Mycapssa Published in The Lancet
    Results from Amyrt’s Phase 3 Trial of Mycapssa Published in The Lancet

    04 Jan 2022

    // TRIALSITENEWS

    https://trialsitenews.com/results-from-amyrt-pharmas-phase-3-mpowered-trial-of-mycapssa-oral-octreotide-for-acromegaly-published-in-the-lancet-diabetes-endocrinology/

    TRIALSITENEWS
    04 Jan 2022
    Share Share
    A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino
    A unicorn joins this week’s stampede of biotechs into the red-hot Nasdaq casino

    16 Jul 2018

    // John Carroll ENDPTS

    https://endpts.com/a-unicorn-joins-this-weeks-stampede-of-biotechs-into-the-red-hot-nasdaq-casino/

    John Carroll ENDPTS
    16 Jul 2018
    Share Share